Literature DB >> 21551250

Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.

Lu Q Le1, Chiachi Liu, Tracey Shipman, Zhiguo Chen, Ueli Suter, Luis F Parada.   

Abstract

Stem cells are under strict regulation by both intrinsic factors and the microenvironment. There is increasing evidence that many cancers initiate through acquisition of genetic mutations (loss of intrinsic control) in stem cells or their progenitors, followed by alterations of the surrounding microenvironment (loss of extrinsic control). In neurofibromatosis type 1 (NF1), deregulation of Ras signaling results in development of multiple neurofibromas, complex tumors of the peripheral nerves. Neurofibromas arise from the Schwann cell lineage following loss of function at the NF1 locus, which initiates a cascade of interactions with other cell types in the microenvironment and additional cell autonomous modifications. In this study, we sought to identify whether a temporal "window of opportunity" exists during which cells of the Schwann cell lineage can give rise to neurofibromas following loss of NF1. We showed that acute loss of NF1 in both embryonic and adult Schwann cells can lead to neurofibroma formation. However, the embryonic period when Schwann cell precursors and immature Schwann cells are most abundant coincides with enhanced susceptibility to plexiform neurofibroma tumorigenesis. This model has important implications for understanding early cellular events that dictate neurofibroma development, as well as for the development of novel therapies targeting these tumors. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21551250      PMCID: PMC3145496          DOI: 10.1158/0008-5472.CAN-10-4577

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

Review 1.  Neurofibromin, a tumor suppressor in the nervous system.

Authors:  Y Zhu; L F Parada
Journal:  Exp Cell Res       Date:  2001-03-10       Impact factor: 3.905

Review 2.  NF1 tumor suppressor gene function: narrowing the GAP.

Authors:  K Cichowski; T Jacks
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

3.  Mouse models of tumor development in neurofibromatosis type 1.

Authors:  K Cichowski; T S Shih; E Schmitt; S Santiago; K Reilly; M E McLaughlin; R T Bronson; T Jacks
Journal:  Science       Date:  1999-12-10       Impact factor: 47.728

4.  Mouse tumor model for neurofibromatosis type 1.

Authors:  K S Vogel; L J Klesse; S Velasco-Miguel; K Meyers; E J Rushing; L F Parada
Journal:  Science       Date:  1999-12-10       Impact factor: 47.728

Review 5.  Neurofibromatosis type 1. I. General overview.

Authors:  M M Lakkis; G I Tennekoon
Journal:  J Neurosci Res       Date:  2000-12-15       Impact factor: 4.164

6.  Associations of clinical features in neurofibromatosis 1 (NF1).

Authors:  J Szudek; P Birch; V M Riccardi; D G Evans; J M Friedman
Journal:  Genet Epidemiol       Date:  2000-12       Impact factor: 2.135

7.  Isolation of multipotent adult stem cells from the dermis of mammalian skin.

Authors:  J G Toma; M Akhavan; K J Fernandes; F Barnabé-Heider; A Sadikot; D R Kaplan; F D Miller
Journal:  Nat Cell Biol       Date:  2001-09       Impact factor: 28.824

8.  Giant plexiform neurofibroma in a patient with neurofibromatosis type I.

Authors:  Efstathios Rallis; Dimitra Ragiadakou
Journal:  Dermatol Online J       Date:  2009-05-15

Review 9.  Neurofibromatosis type 1.

Authors:  Kevin P Boyd; Bruce R Korf; Amy Theos
Journal:  J Am Acad Dermatol       Date:  2009-07       Impact factor: 11.527

10.  Identification of a cell of origin for human prostate cancer.

Authors:  Andrew S Goldstein; Jiaoti Huang; Changyong Guo; Isla P Garraway; Owen N Witte
Journal:  Science       Date:  2010-07-30       Impact factor: 47.728

View more
  40 in total

Review 1.  Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.

Authors:  Steven L Carroll
Journal:  Acta Neuropathol       Date:  2011-12-11       Impact factor: 17.088

Review 2.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

3.  CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors.

Authors:  Wei Mo; Jian Chen; Amish Patel; Liang Zhang; Vincent Chau; Yanjiao Li; Woosung Cho; Kyun Lim; Jing Xu; Alexander J Lazar; Chad J Creighton; Svetlana Bolshakov; Renée M McKay; Dina Lev; Lu Q Le; Luis F Parada
Journal:  Cell       Date:  2013-02-21       Impact factor: 41.582

4.  The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas.

Authors:  A Pemov; H Li; R Patidar; N F Hansen; S Sindiri; S W Hartley; J S Wei; A Elkahloun; S C Chandrasekharappa; J F Boland; S Bass; J C Mullikin; J Khan; B C Widemann; M R Wallace; D R Stewart
Journal:  Oncogene       Date:  2017-01-09       Impact factor: 9.867

Review 5.  Genetic predisposition to peripheral nerve neoplasia: diagnostic criteria and pathogenesis of neurofibromatoses, Carney complex, and related syndromes.

Authors:  Fausto J Rodriguez; Constantine A Stratakis; D Gareth Evans
Journal:  Acta Neuropathol       Date:  2011-12-31       Impact factor: 17.088

6.  EGFR-Stat3 signalling in nerve glial cells modifies neurofibroma initiation.

Authors:  J Wu; W Liu; J P Williams; N Ratner
Journal:  Oncogene       Date:  2016-10-17       Impact factor: 9.867

Review 7.  Neural crest lineage analysis: from past to future trajectory.

Authors:  Weiyi Tang; Marianne E Bronner
Journal:  Development       Date:  2020-10-23       Impact factor: 6.868

8.  Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis.

Authors:  Chung-Ping Liao; Reid C Booker; Jean-Philippe Brosseau; Zhiguo Chen; Juan Mo; Edem Tchegnon; Yong Wang; D Wade Clapp; Lu Q Le
Journal:  J Clin Invest       Date:  2018-05-21       Impact factor: 14.808

Review 9.  Optimizing biologically targeted clinical trials for neurofibromatosis.

Authors:  David H Gutmann; Jaishri O Blakeley; Bruce R Korf; Roger J Packer
Journal:  Expert Opin Investig Drugs       Date:  2013-02-21       Impact factor: 6.206

Review 10.  Modeling cognitive dysfunction in neurofibromatosis-1.

Authors:  Kelly A Diggs-Andrews; David H Gutmann
Journal:  Trends Neurosci       Date:  2013-01-08       Impact factor: 13.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.